A systemic review indicated that the IBD patients who responded to treatment of anti-interleukin or anti-tumor necrosis factor reflecting constantly (both at baseline and throughout the therapy) higher α-diversity and increased relative abundances of certain genera such as Faecalibacterium, Roseburia, or Clostridium (Estevinho et al., 2020). The gene discussed is TNF; the disease is inflammatory bowel disease.